Abstract: The present invention thus provides a novel family of liposomal compositions (nanocarriers), hereinafter referred to as Tetra-Acidosomes, comprising natural tetrameric acid (TA) lipids and/or novel chemically functionalized tetrameric acid (CFTA) lipids, for drug delivery applications. Use of the disclosed Tetra-Acidosomes as well as methods of synthesis of the Tetra-Acidosomes are also disclosed.

Abstract: Disclosed are a soft candy without a fishy taste or odor and a preparation method thereof. The preparation method includes: (1) mixing and stirring a DHA-containing raw oil, a fragrance, and an antioxidant, and allowing a resulting mixture to stand to obtain a DHA-containing mixture; (2) mixing and dispersing a polymeric sugar, an emulsifying agent, and water to obtain an oxygen-isolation preprepared solution; (3) dispersing the oxygen-isolation preprepared solution and the DHA-containing mixture, and allowing a resulting system to undergo equilibrium and stabilization to obtain an oxygen-isolated DHA-containing solution; (4) preparation of a pigment solution and an acid solution; (5) preparation of a sticky syrup; (6) mixing the sticky syrup, the oxygen-isolated DHA-containing solution, the acid solution, and the pigment solution to obtain a sugar-containing slurry; and (7) pouring the sugar-containing slurry into a soft candy mold to obtain the soft candy without a fishy taste or odor.

Abstract: Disclosed herein are topical formulations of cannabidiol, such as nanoparticulate cannabidiol, methods of making such compositions, and their use in treating autoimmune diseases and disorders, e.g., alopecia areata.

Abstract: The present invention relates to a prolonged-release pharmaceutical composition for oral administration of sultiame in the form of particles wherein the amount of sultiame is from 0.5 mg to 5.0 mg per particle, and the particles have a particle size of less than 5000 ?m and comprise an outer layer providing prolonged-release of sultiame. The present invention also relates to the pharmaceutical composition of the invention for use for treating and/or preventing epilepsy.

Abstract: Method of manufacturing, and use of cross-linked polymeric hydrogels as final dosage forms for the oral delivery of compounds with nutritional and/or therapeutic value, including but not limited to supplements, cell-based therapies, and active pharmaceutical ingredients.

Abstract: Leucine zipper-bearing kinase (LZK) targeted degraders are disclosed. The compounds have a general formula Q-L-Z where Q is an LZK binding moiety, L is a linker, and Z is an E3-ligase binding moiety. The compounds inhibit LZK activity and/or degrade LZK. The compounds may be used to treat diseases or conditions characterized at least in part by LZK overexpression.

Abstract: An aspect of the present invention relates to a cosmetic laminate sheet including a thin film sheet that has a thickness of 10 nm or more and 10 ?m or less and is water-permeable and a support that has water absorbing properties and a possible amount of water content in the support being 4.4 g or more per 1 g of the support.

Abstract: A process for dyeing keratinous material, in particular human hair, is provided. The process includes applying an agent (a) to the keratinous material, the agent (a) including at least one organic silicon compound. An agent (b) is applied to the keratinous material. The agent (b) includes (b1) at least one coloring compound including at least one effect pigment including i) a substrate platelet, ii) a metal oxide (hydrate) layer provided on the surface of the substrate platelet, iii) a metal particle carrier layer provided on the surface of the metal oxide (hydrate) layer, and iv) metal particles provided on the surface of the metal particle carrier layer, and (b2) at least one film-forming polymer.

Abstract: The invention relates to the use of a cosmetic composition comprising at least one compound according to Formula (1) wherein R is selected from linear or branched C3-C20-alkyl; and n is selected from 1 to 20; for the cosmetic treatment of skin.

Abstract: The present invention relates to a technological platform for the delivery of lipophilic active ingredients.

Abstract: The present application discloses a composition for the treatment of Painful Damaged Disc Syndrome (PDDS), disc bulge, protrusion and herniation, and a delivery method and recommended treatment protocol for delivering thereto to a subject with an effective dosage of the composition. The composition has anti-inflammatory, antioxidant and vasodilating and antispasmodic properties. The compound is being administered via intravenous drip over a specified period for pain relief.

Abstract: Compositions and methods for wound treatment. Compositions may be formulated as a dry powder. Compositions may include an antibiotic and a metal-containing species. Each of the antibiotic and the metal-containing species may positively modulate wound bed and peri-lesional cellular processes supportive of healing. Methods may include a two-step protocol. The first protocol step may be spreading upon a wound surface an emollient-rich mixture of low-and high-molecular weight (MW) non-water-soluble ingredients of an anti-microbial ointment, forming an occlusive cover over the wound. The second protocol step may be to apply the compositions onto the cover. Low-MW emollients may migrate into, and solubilize components of, the dry powder. The solubilized components and the low-MW emollients may transport below the cover to the wound bed to facilitate effective wound healing. Initial testing and use studies have yielded good wound closures, with minimal-to-no scarring and high regain of function of repaired tissues.

Abstract: A topical preparation for use in treating dermatological ailments is prepared from a mixture comprising salicylic acid or a salt thereof, zinc or a salt thereof, iodine or a salt thereof, and a pharmaceutically acceptable carrier vehicle. The preparation comprises any one or more of anti-inflammatory properties, keratolytic properties, anti-pruritic properties, anti-carcinogenic properties. Methods of treatment involving topical application of the preparation are also described.

Abstract: Provided is a cosmetic composition that includes: (a) at least one surfactant, which includes at least one anionic surfactant; and (b) a fatty acid thickener. The cosmetic composition may be transparent and sulfate free.

Abstract: A method of enhancing the quality of a skin scar by topical application of an agent for improving scar quality is characterised in that said agent is pre-emptively applied to a potential surgical cutaneous site in advance of surgery, including surgery involving use of lasers. The topical agent may be a polyphenol, such as (-)-epigallocatechin-3-gallate (EGCG). Use of such a topical agent in advance of surgery leads to significant beneficial effects on dermal scarring by reducing mast cells, angiogenesis, skin thickness and simultaneously increasing elastin content. The topical agent may be applied directly or incorporated in a dressing, such as in a dermal patch comprising an adhesive silicone sheet, and can be worn both in the lead up to surgery and post-operatively.

Abstract: A liquid-holding edible gummy or edible chew for oral consumption by an individual is disclosed. The gummy is a novel, cost-effective, hollow edible that enables users to consume a desired liquid such as an alcohol shot, a medicine, and more without using conventional bottles, cans, and more. The gummy includes a housing made of a gelling substance and the housing encloses a central cavity which holds a liquid. When the gummy is bitten or chewed, the liquid comes out from the cavity and provides a unique way of consuming the liquid. The gummy can be used as a delivery device for alcohol, medicine, non-alcoholic beverages, etc. The gummy is formed using a mold and the liquid, for example, can be injected inside the cavity through the housing.

Abstract: Provided herein are methods and compositions for modulating a microorganism's response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a microbial infection comprising administering to a subject in need an effective amount of (i) bicarbonate and (ii) an antimicrobial agent. Also provided herein are methods of screening for antimicrobial compounds.

Abstract: Provided are a pharmaceutical composition for preventing or treating a coronavirus infection or infectious disease, a composition for disinfection, and a health functional food or feed composition, all including nano-sized graphene oxide, and a method of using the same. Since the nano-sized graphene oxide or a complex thereof has anti-coronavirus activity, the graphene oxide may be used for prevention or treatment of a coronavirus infection, or disinfection of coronaviruses.

Abstract: Antimicrobial azo compounds include azobenzene monomers having a phenyl ring comprising a hydroxyl substituent group. The azobenzene monomers can be reacted with a polymeric material to form an antimicrobial coating that prevents growth of persistent biofilms. In some implementations, the azobenzene monomers can be used to coat the surface of a dental resin-based composite to prevent the formation secondary caries. In some implementations, the azobenzene coating can be used to disperse microbial biofilms through a photofluidization process (rapid photoisomerization) in addition to biochemically preventing formation of the microbial biofilm.

Abstract: Compositions comprising starch-acrylic polymers combined with elemental iodine are disclosed. The SAP-I compositions release non-toxic amounts of iodophor iodine in a sustained, controlled manner. Methods of formation and use of the compositions along with methods of creation and use of devices incorporating the compositions in a variety of healthcare and non-healthcare settings are set forth in detail herein.